Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Healthy
Interventions: Brain Computer Interface Switch; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Smoking Cessation, Alcohol Drinking
Interventions: Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV-1-infection
Interventions: no intervention; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Safety Issues
Interventions: Nicotine Bitartrate Lozenge 4mg, Nicotine Polacrilex 4Mg Lozenge; Drug
Lead sponsor: Niconovum USA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets (20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 16
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 2 more

Conditions: Cystic Fibrosis
Interventions: hypertonic saline (7%), isotonic saline; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Substance Abuse
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions: Buprenorphine/naloxone, Placebo Oral Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Heavy Drinking, Driving Under the Influence, Riding With Driver Under the Influence
Interventions: Computer-facilitated Screening and Brief Intervention; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 17 Years
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Itasca, Illinois • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: STAKEL; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas

Conditions: Influenza
Interventions: Quadrivalent VLP Vaccine, Comparator TIV; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Myotonic Dystrophy 2
Interventions: Exercise; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Weight Loss, Pediatric Obesity, Overweight Adolescents, Parent-Child Relations, Family and Household
Interventions: Brenner FIT Standard, By Design Essentials, Dyad Plus; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 13 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Frozen Shoulder
Interventions: Methylprednisolone Injectable Product, Doxycycline Injection; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HER2-positive Gastric Cancer
Interventions: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel, Cinrebafusp alfa (PRS-343) in combination with tucatinib; Drug
Lead sponsor: Pieris Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Santa Barbara, California • Silver Spring, Maryland • New York, New York + 1 more

Conditions: Salt-sensitive Hypertension
Interventions: Fenoldopam; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Allergic Conjunctivitis
Interventions: TL-925, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Multiple Sclerosis, Pain, Fatigue Symptom
Interventions: Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Caries
Interventions: Calcium sodium phosphosilicate, Sodium monoflurophosphate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Emotion Regulation
Interventions: Laboratory tasks in early adolescence; Behavioral
Lead sponsor: Miami University; Other
Eligibility: 10 Years to 15 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Oxford, Ohio

Search by objective public record fields.

Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Longer-Acting PrEP in Transgender and Gender Diverse Texans

Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 2

HIV, Buprenorphine, and the Criminal Justice System

Adolescent Substance Use Prevention Intervention Research Study in Pediatric Primary Care

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

Dyad Plus Effectiveness/Feasibility

Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Usability of the MeTime MS App

Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

From Toddler to Early Adolescent Emotion Regulation Strategies